Hohimer Wealth Management LLC Makes New $6.69 Million Investment in Incyte Corporation $INCY

Hohimer Wealth Management LLC acquired a new stake in Incyte Corporation (NASDAQ:INCY) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 55,100 shares of the biopharmaceutical company’s stock, valued at approximately $6,686,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Trails Edge Capital Partners LP bought a new position in Incyte in the 2nd quarter valued at about $17,570,800. Twin Capital Management Inc. acquired a new stake in Incyte during the first quarter worth approximately $875,000. Tidal Investments LLC lifted its position in Incyte by 33.4% during the second quarter. Tidal Investments LLC now owns 102,834 shares of the biopharmaceutical company’s stock worth $11,657,000 after acquiring an additional 25,768 shares during the last quarter. BlackRock Inc. bought a new stake in shares of Incyte during the second quarter worth approximately $2,044,189,000. Finally, Mediolanum International Funds Ltd boosted its holdings in shares of Incyte by 25.4% during the first quarter. Mediolanum International Funds Ltd now owns 60,300 shares of the biopharmaceutical company’s stock worth $5,447,000 after acquiring an additional 12,227 shares during the period. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Leerink Partners reaffirmed its Buy rating and set a $150 price target, indicating confidence in Incyte’s prospects. Article
• Positive Sentiment: Incyte plans to present new hematology data at ASH 2026. Canaccord Genuity maintained its Buy rating and $152 target, citing upcoming data for ’989 as support for its view; the results could provide updates on pipeline potential. Article Analyst report
• Neutral Sentiment: Incyte raised Bernstein’s price target to $108 from $104. The increase is modest, and the new target remains below the recent share price. Article
• Neutral Sentiment: The company awarded grants supporting projects focused on graft-versus-host disease (GVHD). The program underscores its engagement in the area but is unlikely to materially affect near-term revenue. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, retaining more than 21,000 shares afterward. The planned, relatively small sale offers limited directional signal. Article

Wall Street Analyst Weigh In

Several equities analysts have recently commented on INCY shares. Barclays upped their target price on Incyte from $139.00 to $143.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Sanford C. Bernstein lifted their price target on Incyte from $104.00 to $108.00 and gave the stock a “market perform” rating in a report on Monday, November 2nd. Stifel Nicolaus lifted their price target on Incyte from $145.00 to $157.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Leerink Partners reduced their price target on Incyte from $154.00 to $150.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, UBS Group set a $152.00 price objective on Incyte in a report on Friday, October 30th. Eleven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $132.86.

Incyte Price Performance

Shares of Incyte stock opened at $119.65 on Monday. Incyte Corporation has a twelve month low of $89.25 and a twelve month high of $132.60. The company has a 50-day simple moving average of $119.62 and a two-hundred day simple moving average of $108.51. The stock has a market capitalization of $24.39 billion, a price-to-earnings ratio of 63.64, a price-to-earnings-growth ratio of 4.36 and a beta of 0.78.

Incyte (NASDAQ:INCY) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. During the same quarter in the prior year, the business posted $2.26 EPS. The business’s revenue was up 14.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Incyte Corporation will post 2.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Thomas Tray sold 610 shares of the business’s stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares in the company, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo J. Cagnoni sold 2,642 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $112.71, for a total value of $297,779.82. Following the sale, the insider directly owned 183,200 shares in the company, valued at $20,648,472. This represents a 1.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 14,053 shares of company stock valued at $1,726,519. 16.20% of the stock is owned by company insiders.

About Incyte

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally.

Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.